Labiotech.eu’s Post

🚀 Myricx Bio's recent £90m funding for cancer therapy. 🎯 Focused on NMTi inhibitor ADCs, they're gearing up to bring novel treatments to clinical trials. 🧬 With a solid start and the backing of giants like Novo Holdings, Abingworth, and Eli Lilly & Co, Myricx is all set to expand its R&D horizons. 🌱 This cash infusion is more than money; it's hope for groundbreaking cancer treatments. Could this be the dawn of the next big leap in oncology? 🔬💊 #CancerResearch #PrecisionMedicine #InnovationInHealthcare

Welcome to our newest portfolio, T-Therapeutics Ltd, who announced today a £48 million Series A financing led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital (CIC) with participation from Sanofi Ventures and the University of Cambridge Venture Fund. The proceeds will be used to discover and develop novel T cell receptor (TCR) therapeutics for cancer indications as well as inflammatory disorders.  T-Therapeutics' proprietary transgenic mouse platform, OpTiMus®, creates an almost unlimited repertoire of ‘optimal’ TCRs as building blocks for pioneering therapies. These treatments are being designed to recognise specific cancers and recruit the patient’s own T cells to eradicate tumors. T-Therapeutics will also develop medicines that address various auto-immune disorders. Their approach, developed by an expert team with a proven track record in antibody engineering and drug development, aligns with Sofinnova’s commitment to transformative healthcare solutions. Professor Allan Bradley, CEO of T-Therapeutics, commented: “We’re delighted to have raised this Series A with such high-quality investors whose amazing networks and shared vision will help us deliver highly differentiated TCR cancer therapies.” Congratulations to Professor Allan Bradley and the entire team. We're thrilled to support and witness the unfolding of a new chapter in cancer treatment. Read more: https://hubs.ly/Q028YQTK0 Graziano Seghezzi #Innovation #Healthcare #CancerTherapy

Biotech innovations are driving new treatments for pancreatic cancer, one of the deadliest cancers. A blood test now detects early-stage pancreatic cancer with 97% accuracy. Impact - ▪️ Oncolytics Biotech: Pelareorep advances with FDA Fast Track designation and $5M award. ▪️ Candel Therapeutics: CAN-2409 doubles median survival in phase 2 trials. ▪️ ABVC BioPharma: New collaboration with OncoX aims to deliver transformative treatments. Think About - ▪️ How will early detection tests reshape treatment? ▪️ Can biotech collaborations set new therapy standards?

𝐓𝐎𝐑𝐋 𝐁𝐢𝐨𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐑𝐚𝐢𝐬𝐞𝐬 $𝟏𝟓𝟖𝐌 𝐟𝐨𝐫 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 TORL BioTherapeutics TORL BioTherapeutics, LLC, a clinical-stage biotech company focused on developing antibody-based immunotherapies for cancer, announced the successful closure of an oversubscribed $158 million Series B-2 financing round. Led by Deep Track Capital, with participation from prominent biotech investors including RA Capital Management and Perceptive Advisors, alongside existing investors, the round brings the total raised to over $350 million. The funds will primarily support the advancement of TORL-1-23, an antibody-drug conjugate (ADC) targeting CLDN 6+ tumors, through Phase 1 and a pivotal Phase 2 trial starting in the second half of 2024 for platinum-resistant ovarian cancer. Additionally, resources will be allocated to ongoing Phase 1 studies for TORL-2-307, TORL-3-600, and TORL-4-500, targeting various cancer types. Mark Alles , TORL's Chairman and CEO, expressed gratitude for the continued support from existing investors and welcomed new partners to the TORL team, emphasizing the company's commitment to delivering breakthrough therapies. Rebecca Luse Rebecca Luse from Deep Track Capital highlighted confidence in TORL's scientific and business expertise, noting the promising potential of the ADC pipeline in oncology. Dr. Dennis Slamon Dennis Slamon, TORL's Board Member and Scientific Co-founder, underscored the company's foundation on decades of cancer research, aiming to address unmet medical needs globally. Dave Licata Dave Licata, TORL's President and CFO, emphasized the significance of the financing in advancing pivotal trials and driving long-term value for investors and patients. #therapeutics #cancertreatment #clinicaltrials #financing #immunotherapy #investment #medical #patient

#News: Halda Therapeutics, a Connecticut-based biotech founded by Yale professor and entrepreneur Craig Crews, announced Monday that it has raised $126 million in a #SeriesB extension to move two candidates into #clinicaltrials for patients with #prostate and #breast #cancer. The #biotech has been developing a new class of #cancertherapies known as #RegulatedInducedProximityTargetingChimeras (RIPTAC). According to Halda, these assets use a “hold and kill” mechanism using two proteins, one cancer-specific and one with an essential function. The candidates are designed to help retract essential cell function and cause the death of the cancer cells while preserving non-cancer tissue. “This financing will enable us to bring to patients our oral, selective and widely applicable cancer cell-killing mechanism that is designed to overcome drug resistance, which is a major shortcoming of many current standard of care cancer treatments,” Kat Kayser-Bricker, Halda chief scientific officer, said in a statement. Read more from BioSpace 👇🏼

🚀 Breaking news in the pharma world! Boehringer Ingelheim has acquired Nerio Therapeutics for up to $1.3 billion, significantly bolstering our immuno-oncology pipeline. This acquisition includes Nerio’s advanced preclinical program, which will be a cornerstone in developing innovative cancer treatments. 💡 Nerio Therapeutics, known for its pioneering work with phosphatases, brings to the table novel checkpoint inhibitors that expand our repertoire of potential cancer therapies. As Paola Casarosa, a member of our board of managing directors, stated, this move creates a broad panel of exciting new cancer treatment combination opportunities. 🧬 We’re thrilled to integrate Nerio’s small molecule PTPN1/N2 inhibitors into our portfolio. These inhibitors are designed to activate the immune system to combat cancer cells, offering a first-in-class opportunity with superior drug-like properties. This acquisition aligns perfectly with our mission to extend the benefits of immuno-oncology to more patients, potentially providing single-agent therapy solutions. 👏 A big shoutout to Sanford Madigan, co-founder and CEO of Nerio Therapeutics, and his team for their groundbreaking work. We’re excited to continue this journey together and unlock the full potential of these compounds in the fight against cancer. #BoehringerIngelheim #NerioTherapeutics #ImmunoOncology #CancerResearch #PharmaInnovation #Healthcare

What a day for biotech financings! CatalYm GmbH, one of four companies who raised a megaround today, snagged an $150-million series D to move its GDF-15 inhibitor visugromab into first-line lung cancer patients. The protein plays a key role in fetomaternal tolerance, but cancer can hijack that mechanism to avoid immune detection, CEO Phil L'Huillier told me. Targeting GSF-15 also has another benefit -- it can reduce the nausea and vomiting triggered by other cancer treatments. “When we neutralise GDF-15 to treat cancer, not only are we treating the cancer through the immune mechanism, but we’re also treating the sickness that’s often associated with chemotherapies, radiotherapies, and ADCs ,” L'Huillier explained. For more on CatalYm's clinical plans and the American Society of Clinical Oncology (ASCO) data that triggered Tuesday's round, read the story here: https://lnkd.in/gDcHZQUm

Sharing an interesting article on Delphia Therapeutics new area of cancer biology, activation lethality. Delphia integrates tumor genetics, novel functional genomic approaches, and studies of inhibitor drug resistance to identify targets that drive activation lethality. Through its activation lethality platform, Delphia is advancing a pipeline of first-in-class cancer medicines that aim to better control oncogenic pathways. Delphia completed a $67 million Series A financing led by premier early life sciences investors including GV (Google Ventures), Nextech Invest Ltd , Polaris Innovations Fund and Alexandria Venture Investments. Looking for commercialization consulting for your Phase 1b - 3 emerging biotech? Check out my site www.bridge1.net. Let me help you manage the roadblocks to commercialization success. #commercialization #oncology #cancer #cancertreatment #lethality #tumorgenetics https://lnkd.in/dNjH6GcR

[News] Biocytogen Announces Collaboration with IDEAYA Biosciences We are pleased to announce a new collaboration with IDEAYA Biosciences on a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (BsADC) program. IDEAYA Biosciences is a precision medicine oncology company developing targeted therapies for patient populations identified through molecular diagnostics and synthetic lethality. This program targets B7H3/PTK7, which is co-expressed in multiple solid tumors, including lung, colorectal, and head and neck cancers, offering promising therapeutic opportunities. This partnership combines Biocytogen’s cutting-edge RenLite® platform and proprietary linker-payload technology with IDEAYA's expertise in DNA Damage Repair (DDR) therapeutics. By leveraging our shared strengths, we aim to advance cancer treatments through innovative therapeutic strategies. Biocytogen is committed to advancing the B7H3/PTK7 BsADC program towards development candidate nomination in the second half of 2024. Our collaboration with IDEAYA underscores our dedication to pioneering novel therapeutics for cancer treatment. #Biocytogen #IDEAYA #CancerTherapy #Oncology #BsADC #Innovation #RenLitePlatform #DDR #Biotechnology

SynAI is an AI-driven platform designed to predict the synergistic effects of cancer drug combinations, poised to fundamentally change how we discover and evaluate cancer treatments. At its heart, SynAI is about predicting the combined effects of cancer drugs, known as drug synergism. This AI-driven solution is trained with over 1.2 million in vitro tests across different cancer cell lines, flexible and innovative, focusing on early-stage drug discovery to identify the therapeutic potential of various compound combinations. Learn more about SynAI in the blog post. #CancerResearch #Oncology #DrugDiscovery #AI #Innovation #Bioscience #Biotech